DiagnaMed Expands with Drug and Clinical Research AI Platform
DiagnaMed Holdings Corp. (“DiagnaMed” or the “Company”) (CSE: DMED) (OTCQB: DGNMF), a healthcare technology company dedicated to brain health through AI, is excited to announce the expansion of its innovative BRAIN AGE Brain Health AI Platform. This expansion utilizes proprietary EEG data from past and future research studies to develop a potential drug discovery and clinical research AI platform. EEG technology offers a real-time view of brain-wave activity across various regions and can effectively measure how drugs impact the brain. By harnessing BRAIN AGE, the Company aims to enhance patient recruitment for clinical trials, streamline data analysis, inform drug development decisions, and explore new treatment avenues for neurological, psychiatric, and infectious diseases.
Clinical Validation of BRAIN AGE Brain Health AI Platform
The BRAIN AGE Brain Health AI Platform estimates brain age by capturing brain-wave activity from multiple regions and processing this data with a proprietary machine-learning model. Certain medications that affect the brain can create a consistent EEG response, which can be leveraged to develop new drug analogs and explore potential drug repurposing opportunities. By examining the effects of drugs on brain activity through EEG, researchers can categorize and identify medications based on their mechanisms of action.
Moreover, BRAIN AGE Brain Health AI can determine whether a brain is aging faster or slower than what is typical for healthy individuals. This estimation is achieved by collecting neural activity data using an affordable and user-friendly electroencephalogram headset and analyzing it with a proprietary machine-learning model. Additionally, the platform can evaluate if a person has a healthy brain or is beginning to experience cognitive decline. Brain health assessments are based on clinically validated metrics that measure resilience, vulnerability, and performance functions. This allows individuals to access personalized diagnostics and interventions, such as medications or lifestyle changes, that could help slow down or prevent cognitive decline.
Research and Development Advances
A peer-reviewed paper published in Frontiers in Neuroergonomics, titled "Brain-age estimation with a low-cost EEG-headset: effectiveness and implications for large-scale screening and brain optimization," highlights the clinical potential of BRAIN AGE. The study emphasizes that this platform serves as a cost-effective method for screening large populations for susceptibility to age-related cognitive decline. Regular screenings can track changes over time, evaluate the effectiveness of treatments, and assess lifestyle changes aimed at improving brain performance.
About DiagnaMed
DiagnaMed Holdings Corp. (CSE: DMED) (OTCQB: DGNMF) is a healthcare technology company focused on enhancing brain health through AI. The Company is commercializing the BRAIN AGE Brain Health AI Platform, a pioneering consumer solution that estimates brain age and provides a brain health score. For more information, visit DiagnaMed.com.
Contact Information
If you would like to learn more, please reach out to:
Fabio Chianelli
Chairman and CEO
DiagnaMed Holdings Corp.
Tel: 416-800-2684
Email: info@diagnamed.com
Website: www.diagnamed.com
Frequently Asked Questions
What is the BRAIN AGE platform?
The BRAIN AGE platform is an AI-powered tool designed to estimate brain age and provide insights into brain health using EEG data.
How does the BRAIN AGE platform work?
This platform captures brain-wave activity through a low-cost EEG headset and utilizes machine learning to analyze the collected data.
What types of diseases can the platform help research?
It aims to facilitate the discovery of treatments for neurological, psychiatric, and infectious diseases by enhancing the efficiency of clinical trials.
What is the significance of EEG data?
EEG data offers a real-time assessment of brain activity, enabling researchers to evaluate drug effects and identify their mechanisms of action.
How can individuals benefit from the BRAIN AGE platform?
Individuals can access personalized diagnostics and interventions that may assist in reducing cognitive decline and improving overall brain health.
